Innovent initiates pivotal Phase III trial of IBI363/TAK-928 with bevacizumab for late-line metastatic colorectal cancer in China, advancing a novel immuno-oncology bispecific approach
Executive summary: Innovent Biologics announced the first patient was dosed in a pivotal registrational study of IBI363/TAK-928, a PD-1/IL-2α-biased bispecific fusion protein, combined with bevacizumab for the treatment of late-line advanced colorectal cancer in China. The trial evaluates a novel immunotherapy designed to enhance anti-tumor immunity while reducing the toxicities of systemic IL-2, addressing an unmet need in refractory colorectal cancer; positive results could support regulatory approval and commercialization in a major oncology market.
Who is involved: Innovent Biologics (HKEX: 01801) is the sponsor; Takeda Pharmaceuticals is the collaborator on TAK-928; the trial is being conducted in China with bevacizumab (Avastin) as the backbone therapy.
Likely next: Patient enrollment will continue; interim efficacy and safety data are expected in 12–18 months; if successful, Innovent may pursue regulatory submissions in China and potentially globally.
Innovent Biologics has dosed the first patient in a pivotal registrational study evaluating IBI363/TAK-928, a PD-1/IL-2α-biased bispecific fusion protein, in combination with bevacizumab for patients with advanced colorectal cancer who have progressed on prior therapies in China. The trial marks a significant step in the clinical development of a novel immune-modulating biologics designed to enhance T-cell activity while mitigating systemic toxicity associated with conventional IL-2 therapies. This approach reflects a broader industry trend toward engineered cytokine modalities to improve the safety and efficacy of immunotherapy in solid tumors. Success could position Innovent as a leader in next-generation immuno-oncology therapeutics, particularly in colorectal cancer where treatment options remain limited in later lines.
Timeline
- — Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China (PR Newswire)
- — Global Agriculture Tractor Market Sales to Reach 2.61 Million Units by 2031, China and India Drive Nearly Half of Global Tractor Sales - Arizton (PR Newswire)
Analysis — what this means
Likely next events
- Interim analysis of progression-free survival expected by Q3 2027
- Potential regulatory submission in China by late 2028 if primary endpoints are met
- Presentation of early safety data at ASCO GI 2027
Sectors affected
- Oncology therapeutics
- Bispecific antibodies
- Colorectal cancer treatment
- Immuno-oncology combinations
Regulatory implications
- Combination with bevacizumab may support accelerated approval pathway in China
- Global regulatory alignment (FDA/EMA) may be pursued post-China approval
Historical parallels
- Similar to the development trajectory of tebotelimab (PD-1/LAG-3) in gastrointestinal cancers, 2021–2024
- Parallels early-phase studies of NKTR-214 (bempegaldesleukin) in solid tumors, 2018–2020
- Resembles the clinical path of atezolizumab + bevacizumab in hepatocellular carcinoma (IMbrave150, 2020)
Key entities
Sources
- Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China — PR Newswire
- Global Agriculture Tractor Market Sales to Reach 2.61 Million Units by 2031, China and India Drive Nearly Half of Global Tractor Sales - Arizton — PR Newswire